TROG Cancer Research
Members Login   CQMS Login

TROG 14.02 (RAIDER)

Primary sponsor: The Institute of Cancer Research (UK)
Collaborating group: Trans Tasman Radiation Oncology Group (TROG)

Title

A randomised phase II trial of adaptive image guided standard or dose escalated radiotherapy in the treatment of transitional cell carcinoma of the bladder

Summary

Radiation treatment alone or in combination with chemotherapy can cure bladder cancer. The higher the radiation dose to the tumour the higher the chances of curing the cancer, however, higher doses to surrounding normal organs increases risks of side effects. The investigators plan to use daily imaging to determine the optimal radiation treatment for a multi-centre international clinical trial comparing this approach with standard care.

Participating centres

Current participating centres (PDF)

Accrual target

240 (60 TROG)

Current accrual

Current accrual graph (PDF

Expected date of accrual completion

December 2018

Trial chairperson

A/Prof Farshad Foroudi, Olivia Newton John Cancer Centre, VIC

Trial contact

Patrick Wheeler
TROG Trial Coordinating Centre
Phone: +61 2 4014 3903
Email: RAIDER@trog.com.au

Further information

TROG trial 14.02 on Australian Cancer Trials website

Trial resources for TROG members

TROG 14.02 member page

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.